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The LDL receptor (LDLR) plays a central role in coordinating the 
trafficking of circulating cholesterol by mediating the uptake of 
LDL, the major cholesterol-carrying lipoprotein. Mutations in 
LDLR cause familial hypercholesterolemia (FH), an autosomal 
dominant disorder characterized by severe hypercholesterolemia 
and premature coronary atherosclerosis (1). Individuals with 2 
mutant LDLR alleles (FH homozygotes) often develop symp-
tomatic heart disease in childhood (1). In 1973, Khachadurian 
and Uthman described a Lebanese family with an autosomal 
recessive form of severe hypercholesterolemia that was clinically 
indistinguishable from FH (2). Subsequently, patients with a 
similar phenotype were identified in England (3), Sardinia (4), 
and Japan (5), and the disease was named autosomal recessive 
hypercholesterolemia (ARH). Garcia et al. (6) used linkage analysis 
to identify the causative gene, ARH, which encodes an adaptor 
protein called ARH (also known as the LDLR adaptor protein) 
that couples the LDLR to the endocytic machinery (7–9).
The N-terminal portion of ARH contains a phosphotyro-
sine-binding (PTB) domain that binds to the internalization 
sequence (FDNPVY) in the cytoplasmic tail of the LDLR (7, 8) 
and with phosphoinositides (8), which may link the protein to 
membrane lipids. The C terminal portion of ARH binds 2 of the 
major structural components of the clathrin-coated pit: clathrin 
and AP-2 (7, 8). The interaction with clathrin is mediated by a 
canonical clathrin box motif (LLDLE) that binds the terminal 
domain of the heavy chain of clathrin (7, 8). A second, highly 
conserved motif in the C terminal region binds the β2-adaptin 
subunit of AP-2 (7–9). The AP-2–binding motif in ARH does not 
share obvious homology with other β2-adaptin–binding pro-
teins, but mutagenesis studies suggest that ARH and the arres-
tin proteins bind to the same site on the appendage domain of 
β2-adaptin (10). These studies are consistent with a model in 
which ARH couples the LDLR to the endocytic machinery. The 
model is supported by the observation that the PTB domain 
and either the clathrin box or the AP-2 binding site of ARH are 
required for clustering and internalization of the LDLR (11).
LDL turnover studies have demonstrated that the rate of clear-
ance of LDL from the circulation is similar in subjects with ARH and 
in subjects lacking functional LDLRs (FH homozygotes) (5, 12), 
suggesting that ARH is essential for LDLR-mediated uptake of 
LDL. Despite comparable reductions in the fractional catabolic 
rate (FCR) of LDL, the metabolic and clinical phenotype of ARH 
tends to be less severe than that of FH (1–4, 12–18); plasma levels 
of LDL are lower and the onset of coronary artery disease is usu-
ally later in ARH subjects than in FH homozygotes. ARH patients 
also respond to lipid-lowering agents with a greater reduction in 
plasma levels of LDL than is typically observed in patients with 
homozygous FH.
The molecular basis for the less severe clinical phenotype in ARH 
is not known and is the subject of this paper. The finding that the 
rates of clearance of LDL are similarly depressed in ARH and FH 
subjects implicates the LDL production pathway. LDL is produced 
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as a metabolic by-product of VLDL, a triglyceride-rich lipoprotein 
produced exclusively by the liver. VLDL contains a single copy of 
apoB100 and multiple copies of a much smaller apolipoprotein, 
apoE. Circulating VLDL undergoes lipolysis to form VLDL rem-
nants (also referred to as intermediate-density lipoproteins). VLDL 
remnants are cleared from the circulation by binding to hepatic 
LDLR via apoE rather than apoB. apoE binds the LDLR with a 
higher affinity than does apoB100 (19). Subjects with ARH may 
have a lower plasma level of LDL cholesterol (LDL-C) due to 
increased removal of VLDL remnants from the circulation. Alter-
natively, subjects with ARH may produce fewer VLDL particles, 
resulting in a lower rate of production of LDL.
To address these questions, we examined the metabolism of 
VLDL, VLDL remnants, and LDL using mice in which ARH was 
inactivated (Arh–/– mice) (20). These mice share many of the char-
acteristics of humans with ARH. The FCR of radiolabeled LDL 
in the Arh–/– mice is as low as that of mice lacking LDLR (Ldlr–/– 
mice) (20). Despite the very low rate of clearance of LDL in the 
Arh–/– mice, the plasma levels of cholesterol on a chow diet are only 
modestly elevated compared with those of wild-type animals. Only 
when the Arh–/– mice consume a high-cholesterol diet does plasma 
cholesterol attain the same levels as seen in the Ldlr–/– animals (20). 
Here we show that LDLR-mediated clearance of VLDL is preserved 
both in vivo in ARH-deficient mice and in cultured hepatocytes 
from these animals. Thus, ARH is required for LDLR-dependent 
uptake of LDL but not VLDL in the liver.
Results
Arh–/– mice are protected from sucrose-induced hypercholesterolemia 
and hypertriglyceridemia. Previously we showed that the rate of 
LDL clearance is reduced to similar low levels in chow-fed Arh–/– 
mice and Ldlr–/– mice (20). Despite similar rates of fractional 
LDL clearance in the 2 strains, plasma levels of cholesterol (20) 
and apoB (Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI29415DS1) were 
significantly lower in chow-fed Arh–/– mice than in 
Ldlr–/– mice. To determine whether the lower plas-
ma cholesterol levels of the Arh–/– mice were due 
to differences in VLDL metabolism, we examined 
the effect of increasing VLDL synthesis on plasma 
lipid levels by challenging Arh–/–, Arh+/–, Ldlr–/–, and 
wild-type mice (n = 6 per group) with a high-sucrose 
diet (including 60% sucrose and 20% casein). After 
6 weeks on the diet, plasma levels of cholesterol in 
Arh–/– mice (301 ± 34 mg/dl) were 3-fold higher than 
those of wild-type mice (103 ± 9 mg/dl) but much 
lower than those of Ldlr–/– mice (1148 ± 214 mg/dl; 
Table 1 and Figure 1A). The plasma levels of triglyc-
eride were also higher in Ldlr–/– mice (208 ± 14 mg/dl) 
than in Arh–/– mice (101 ± 12 mg/dl) or wild-type animals 
(75 ± 7 mg/dl). The plasma cholesterol and triglyceride levels in 
Arh+/– mice and wild-type mice were not significantly different 
after sucrose feeding. Thus, a single functional ARH allele was 
sufficient to handle the increase in VLDL production associated 
with a high-sucrose diet.
Next we fractionated the lipoproteins to determine the distribu-
tion of cholesterol among the different lipoprotein particles. The 
cholesterol content of VLDL and LDL was dramatically increased 
in sucrose-fed Ldlr–/– mice, with a greater accumulation in the 
VLDL fractions (Figure 1B). The increase in cholesterol content 
of the VLDL and LDL fractions was much more modest in the 
Arh–/– mice than in the Ldlr–/– animals and occurred primarily in 
particles in the LDL size range.
VLDL synthesis is similar in Arh–/–, Ldlr–/–, and wild-type mice. The 
more modest increase in apoB-containing lipoprotein levels in 
the sucrose-fed Arh–/– mice could be due to lower rates of VLDL 
production in these animals. To test this hypothesis, we injected 
both the chow-fed and sucrose-fed mice with the lipase inhibitor 
Table 1
Lipid levels in plasma and livers of mice fed a high-sucrose diet
	 Plasma	(mg/dl)	 	 Liver	(mg/g)
Genotype		 Cholesterol	 Triglycerides	 Cholesterol	 Triglycerides
Wild type 102.7 ± 8.7 75.0 ± 6.8 5.54 ± 1.26 31.6 ± 5.5
Arh+/– 106.1 ± 4.6 77.2 ± 3.4 5.95 ± 1.26 33.7 ± 9.1
Arh–/– 301.0 ± 33.9 101.2 ± 12.3 6.31 ± 1.26 26.8 ± 6.0
Ldlr–/– 1147.8 ± 214.0 208.1 ± 13.8 8.97 ± 1.19 27.2 ± 0.8
Mice (6 per group) consumed a diet (960237; MP Biomedicals) containing 60.2% 
sucrose, 20% casein, 15% cellulose, 0.3% dl-methionine, 3.5% minerals and vitamins, 
and less than 0.2% fat for 6 weeks. Means ± SD are shown.
Figure 1
Plasma cholesterol and triglyceride levels (A) and lipoprotein choles-
terol levels (B) in sucrose-fed wild-type, Ldlr–/–, Arh+/–, and Arh–/– mice. 
Male Arh–/–, Arh+/–, and wild-type littermates, ages 16–18 weeks, and 
age-matched Ldlr–/– mice (n = 6 per genotype) were fed a high-sucrose 
diet for 6 weeks. Mice were sacrificed and blood was drawn from the 
inferior vena cava. Individual plasma cholesterol and triglyceride levels 
(A) were measured as described in Methods, and the means ± SEM 
are given. (B) Aliquots of plasma from the animals in each group were 
pooled and size fractionated by FPLC. The cholesterol content of each 
fraction was measured as described (39).
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Triton WR-1339 and monitored changes in plasma triglyceride 
and apoB levels. The rates of appearance of triglyceride in the 
plasma were not significantly different (P > 0.38) in the chow-fed 
Arh–/– (1.9 ± 0.7 mg/dl/min), Ldlr–/– (1.7 ± 0.1 mg/dl/min), and 
wild-type mice (1.6 ± 0.1 mg/dl/min) (Figure 2A). On the high-
sucrose diet, the plasma triglyceride levels differed at baseline and 
throughout the experiment among the 3 strains, but the rates of 
increase in triglyceride levels after Triton injection were similar 
in Arh–/– (4.2 ± 0.8 mg/dl/min), Ldlr–/– (4.3 ± 0.7 mg/dl/min), and 
wild-type animals (3.6 ± 1.25 mg/dl/min; P > 0.5) (Figure 2A). The 
relative rates of secretion of apoB determined by Coomassie blue 
staining (Figure 2B) or immunoblotting (data not shown) paral-
leled those of triglyceride secretion: baseline levels of apoB were 
markedly higher in Ldlr–/– mice, but no differences in the rates of 
apoB secretion were evident among the 3 strains. These data do 
not support the notion that the differences in plasma lipid levels 
of Arh–/– and Ldlr–/– mice are due primarily to differences in VLDL 
synthesis and secretion by the liver.
LDLR-dependent clearance of VLDL remnants is partially preserved in 
Arh–/– mice. The LDLR plays a major role in the removal of VLDL 
remnants as well as LDL from the plasma (1). To determine wheth-
er lower cholesterol levels in the Arh–/– mice are due to preserva-
tion of LDLR-mediated VLDL remnant clearance, we measured 
the rates of clearance of 125I-labeled mouse VLDL and rabbit 
β-migrating VLDL (β-VLDL) from the plasma of Arh–/–, Ldlr–/–, and 
wild-type mice (8). The half-life of 125I-labeled mouse VLDL was 
not significantly different in Arh–/– (70 ± 23 minutes) and wild-type 
(64 ± 9 minutes) animals but was longer in Ldlr–/– mice (362 ± 60 
minutes, P < 0.01) (Figure 3A). The clearance of rabbit β-VLDL 
was indistinguishable from that of mouse VLDL in these animals 
(Figure 3A). These data indicate that LDLR-dependent clearance 
of VLDL remnants is preserved in Arh–/– mice.
Since human LDL binds the mouse LDLR with lower affinity 
than mouse LDL (21), we generated a strain of mice expressing the 
human LDLR but no ARH by crossing Arh–/– mice with mice in 
which a human LDLR minigene was inserted into the mouse Ldlr 
locus (hLDLR knockin mice) (22). Since the hLDLR is expressed 
at a 1.3-fold higher level than the wild-type receptor in these 
animals, we used mice heterozygous for the hLDLR minigene 
for these studies. The pattern of clearance of human LDL in mice 
expressing the hLDLR minigene (Figure 3B) was similar to that 
observed previously in wild-type mice using mouse LDL (20). 
The clearance of rabbit β-VLDL was comparable in mice express-
ing the hLDLR minigene and in wild-type animals (Figure 3B) 
and replicated the results obtained with mouse VLDL: The half-
life of rabbit β-VLDL was significantly slower (P < 0.025) in mice 
lacking LDLR (127 ± 30 minutes) but not in those lacking ARH 
(75 ± 16 minutes) compared with mice heterozygous for the 
hLDLR minigene (61 ± 11 minutes).
Hepatocytes from Arh–/– mice internalize VLDL but not LDL. To deter-
mine whether circulating VLDL were taken up by hepatocytes in 
Arh–/– mice, we examined and compared the uptake of colloidal 
Figure 2
VLDL production rates of Arh–/–, Ldlr–/–, and wild-type mice on normal chow and high-sucrose diets. (A) Male Arh–/– (diamonds), Ldlr–/– (circles), and 
wild-type (squares) mice (14–16 weeks of age) were injected with 300 mg/kg Triton WR-1339 (15% w/v in 0.9% NaCl). Prior to injection, the mice 
were maintained on a normal chow diet (left) or a high-sucrose diet (right) for 6 weeks. Blood was sampled from the retro-orbital plexus after a 6-hour 
fast at the time points indicated, and the triglycerides were measured enzymatically as described in Methods. VLDL production rates were calculated 
from the slope of a line determined using least squares regression. (B) apoB production in Arh–/–, Ldlr–/–, and wild-type mice. Male Arh–/– (diamonds), 
Ldlr–/– (circles), and wild-type (squares) mice (n = 4), 18–22 weeks of age, on a chow diet were injected with 300 mg/kg Triton WR-1339 (15% w/v 
in 0.9% NaCl) after a 6-hour fast. Blood was sampled from the retro-orbital plexus at the times indicated. Plasma aliquots from individual mice were 
pooled, and VLDL was separated as described in Methods. The resulting apolipoproteins were separated by SDS-PAGE and stained with colloidal 
Coomassie blue. Scanning densitometry was used to determine the relative amounts of apoB48 and apoB100 in each sample.
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gold–labeled hLDL and β-VLDL in the livers of Ldlrh/h, Ldlrh/hArh–/–, 
and wild-type mice. The mice used in these experiments were homo-
zygous for the human LDLR allele at the Ldlr locus, since hLDL was 
used in these experiments. Gold-labeled LDL particles were present 
in intracellular vesicles (presumed to be endosomes) in the livers 
of wild-type mice but not in Arh–/– mice (Figure 4A). Gold-labeled 
LDL was detected in the sinusoids but not intracellularly in the 
Ldlrh/hArh–/– animals (Figure 4A). In contrast with 
these results, gold-labeled β-VLDL was abundant 
within intracellular vesicles in the hepatocytes 
of the wild-type mice and in mice lacking ARH. 
Hepatocytes from mice lacking LDLRs did not 
internalize LDL (not shown) or β-VLDL (Figure 4B), 
demonstrating that uptake of VLDL remnants 
required expression of the LDLR.
To determine whether the differences in the 
uptake of VLDL remnants and LDL into the 
hepatocytes was cell autonomous, primary 
hepatocytes were isolated from Arh+/+Ldlrh/h, 
Arh–/–Ldlrh/h, and Arh+/+Ldlr–/– mice and incubated 
with fluorescently labeled hLDL and β-VLDL. 
Both 3-pyrenemethyl-23, 24-dinor-5-cholen-22-
oate-3 beta-yl oleate (PMCA-O) LDL and 1,1'-
dioctadecyl-3,3,3',3′-tetramethylindocarbocya-
nine perchlorate (DiI) β-VLDL were efficiently 
taken up by Arh+/+Ldlrh/h hepatocytes (Figure 5). 
Hepatocytes from the Arh–/–Ldlrh/h animals failed 
to internalize any PMCA-O LDL but took up sig-
nificant amounts of DiI β-VLDL (Figure 5). As 
expected, hepatocytes lacking LDLRs failed to 
internalize either ligand. These results indicate 
that LDLR-dependent uptake of VLDL remnants 
is preserved in hepatocytes from Arh–/– animals.
High-affinity binding is not sufficient for ligand uptake by LDLRs in Arh–/– 
hepatocytes. β-VLDL binds the LDLR with greater affinity than 
does LDL (23). To determine whether greater affinity for the recep-
tor is sufficient for internalization of ligand by the LDLR in the 
absence of ARH, we incubated primary hepatocytes with IgG-C7, 
a monoclonal antibody with high affinity for the LDLR (24), 
for 1 hour at 4°C and then for 2 hours at 37°C. After the 4°C 
incubation, LDLR was detected exclusively on the surface of both 
Arh–/–Ldlrh/h and Arh+/+Ldlrh/h hepatocytes (Figure 6A). After warm-
ing the cells to 37°C, the IgG-C7 was redistributed from the cell 
surface to perinuclear vacuoles in the Arh+/+Ldlrh/h hepatocytes. 
In contrast, almost all the IgG-C7 remained associated with the 
cell surface in the Arh–/–Ldlrh/h hepatocytes. No specific staining 
was detected in the Arh+/+Ldlr–/– cells or when using an irrelevant 
antibody, IgG-2001 (data not shown). Thus, despite binding with 
Figure 3
Clearance of circulating VLDL but not LDL is partially preserved in Arh–/– 
mice. (A) Clearance of mouse 125I-VLDL and rabbit 125I–β-VLDL in 
Arh–/–, Ldlr–/–, and wild-type mice. Four wild-type (squares), Arh–/– 
(diamonds), and Ldlr–/– (circles) 12- to 14-week-old female mice were 
injected with mouse 125I-VLDL (125 cpm/ng protein) (left) or rabbit 
125I–β-VLDL (288 cpm/ng protein) (right). Blood samples were col-
lected by retro-orbital puncture at the indicated times, and the plasma 
content of isopropanol-precipitable 125I-radioactivity was measured. 
Radioactivity remaining in the plasma was plotted as a percentage 
of the activity present 2 minutes after injection of the labeled ligand. 
Before the experiment, the mice were fasted for 6 hours and anesthe-
tized with sodium pentobarbital (80 mg/kg intraperitoneal). (B) Female 
Arh+/+Ldlrh/+ (squares), Arh–/–Ldlrh/+ (diamonds), and Ldlr–/– (circles) 
mice (n = 4 per genotype), aged 12–14 weeks, were fasted for 4 hours, 
anesthetized with sodium pentobarbital (80 mg/kg of intraperitoneal), 
and injected with 15 μg 125I-human LDL (125 cpm/ng protein) (left) or 
15 μg 125I-rabbit β-VLDL (189 cpm/ng protein) (right). Blood samples 
were collected and processed as described above.
Figure 4
Localization of LDL-gold (A) and β-VLDL–gold (B) in Ldlrh/h, Ldlrh/hArh–/–, and Ldlr–/– mice. 
Mice were injected via the tail vein with 50 μg of colloidal gold–labeled human LDL or 
rabbit β-VLDL. After 2 hours, mice were sacrificed. Livers were perfused, fixed, and then 
processed for electron microscopy as described in Methods. Solid arrows indicate gold 
particles associated with villi on the sinusoidal membrane, and open arrows indicate 
endosomes. Scale bars: 0.5 μm.
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high affinity to the LDLR, IgG-C7 failed to be internalized in a 
fashion similar to that of β-VLDL in Arh–/– cells.
In addition to having a higher affinity for the LDLR, β-VLDL 
also contains multiple copies of apoE, each of which is capable of 
binding the receptor. Thus, a single β-VLDL particle may simul-
taneously bind multiple LDLRs (25). In contrast, LDL has only 
a single copy of apoB100 and binds the LDLR with a one-to-one 
stoichiometry. To determine whether multivalency of the ligand 
is sufficient for LDLR internalization in the absence of ARH, 
we created a multivalent ligand by incubating the monoclonal 
antibody IgG-C7 with protein A. Protein A has 4 high-affin-
ity IgG-binding sites and should form a tetrameric ligand for 
the LDLR when incubated with IgG-C7. The protein A:IgG-C7 
tetramers were incubated with primary hepatocytes at 4°C for 
1 hour. At 4°C, the tetramers were only detected at the cell sur-
face in the Arh+/+Ldlrh/h and Arh–/–Ldlrh/h hepatocytes. The cells 
were then warmed to 37°C for 2 hours. After warming to 37°C, 
protein A:IgG-C7 was no longer observed on the cell surface of 
Arh+/+Ldlrh/h hepatocytes and was apparent in punctate vesicles 
within the cell (Figure 6B). In contrast, the IgG-C7 tetramers 
remained at the cell surface of the Arh–/–Ldlrh/h hepatocytes after 
warming to 37°C. No specific staining was observed in the 
Arh+/+Ldlr–/– hepatocytes (Figure 6B) or when an irrelevant anti-
body:protein A complex was used.
LDLR-related protein is not required for β-VLDL uptake by Arh–/– 
hepatocytes. It is also possible that the LDLR binds VLDL and 
then transfers it to (or forms a complex with) a second recep-
tor on the cell surface, such as the LDLR-related protein (LRP), 
for internalization. In this model, an alternative adaptor that 
recognizes the cytoplasmic tail of LRP could mediate internal-
ization of the complex, obviating the requirement for ARH. To 
test this hypothesis, we examined the effects of LRP deletion 
on β-VLDL uptake in ARH-deficient animals. Mice lacking ARH 
were crossed with mice containing loxP sites at the LRP locus 
(26, 27) to generate Arh–/–Lrplox/lox animals. LRP was selectively 
deleted in the livers of these animals by introduction of a trans-
gene expressing Cre recombinase (Arh–/–Lrplox/loxCre+) under the 
control of the albumin promoter (28). Deletion of LRP markedly 
impaired clearance of α2-macroglobulin, an established ligand 
for LRP, but did not affect clearance of VLDL remnants in Arh–/– 
animals. Primary hepatocytes from Arh–/–Lrplox/loxCre– mice 
internalized both β-VLDL and α2-macroglobulin (Figure 7). 
Deletion of LRP in these cells did not reduce the uptake of β-
VLDL despite abolishing the internalization of α2-macroglobu-
lin. These findings indicate that the LDLR-dependent internal-
ization of β-VLDL in Arh–/– hepatocytes does not require LRP.
Discussion
In this study, we showed that VLDL but not LDL is rapidly 
removed from the circulation and internalized by hepatocytes 
of Arh–/– mice. Previously, we showed that ARH is required for 
LDLR-mediated clearance of LDL; the FCR of LDL in mice lack-
ing ARH (Arh–/– mice) is equivalent to that of mice lacking LDLRs 
(Ldlr–/– mice) (20). Here we show that the clearance of circulating 
VLDL remnants is largely preserved in mice lacking ARH. As a 
result, Arh–/– mice have near normal plasma levels of cholesterol 
on chow diets and are significantly protected from the hypercho-
lesterolemic effects of a sucrose-rich diet. These data indicate that 
the requirements for hepatic LDLR function are ligand specific. 
ARH is required for internalization of the LDLR in the absence of 
ligand or in the presence of monovalent ligands such as LDL or the 
monoclonal antibody C7 but not for internalization of VLDL rem-
nants. The preservation of VLDL remnant clearance by ARH-defi-
cient hepatocytes likely contributes to the reduced clinical severity 
observed in individuals with ARH compared with patients with no 
LDLR function (1–4, 13–18).
Figure 5
PMCA-O LDL and DiI β-VLDL uptake by primary 
hepatocytes from Arh+/+Ldlrh/h, Arh–/–Ldlrh/h, and Ldlr–/– 
mice. On day 0, primary hepatocytes were isolated 
from Arh+/+Ldlrh/h, Arh–/–Ldlrh/h, and Ldlr–/– mice and 
incubated overnight in DMEM containing 5% lipopro-
tein-deficient serum. The next morning, the cells were 
incubated at 37°C in fresh media containing 25 μg 
PMCA-O LDL and 25 μg DiI β-VLDL for 5 hours. The 
cells were washed, fixed, and mounted as described 
in Methods. Images were procured by deconvolution 
microscopy. Original magnification, ×84.
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The phenotype of mice fed a high-sucrose diet resembles that 
of mice expressing high levels of the sterol regulatory element 
binding protein-1a (SREBP-1a) (29). Overexpression of SREBP-1a 
in the liver leads to increased expression of enzymes in the fatty 
acid biosynthetic pathway, massively increasing the biosynthe-
sis of fatty acids, resulting in severe hepatic steatosis. Despite 
marked increases in VLDL secretion, overexpression of SREBP-1a 
does not increase circulating lipoprotein levels except when the 
LDLR is inactivated. Mice that overexpress SREBP-1a and lack 
functional LDLR are extremely hyperlipidemic (29). In similar 
fashion, mice fed high-sucrose diets do not become hyperlipid-
emic despite substantially increased secretion of VLDL into the 
circulation, as long as LDLR function is intact (29). Thus, the rel-
ative resistance of Arh–/– mice to the hypercholesterolemic effects 
of the high-sucrose diet indicates that LDLR-dependent clear-
ance of VLDL is preserved in these animals. Comparison of the 
plasma lipoprotein profiles of sucrose-fed Arh–/– and sucrose-fed 
Ldlr–/– mice also reveals an important qualitative difference: the 
mice lacking LDLRs accumulate primarily VLDL-
sized particles whereas most of the particles that 
accumulate in the Arh–/– mice are LDL (Figure 1). 
Taken together, these results indicate that the 
LDLR internalizes both VLDL and LDL and that 
LDLR-dependent uptake of VLDL but not LDL is 
preserved in Arh–/– mice.
Electron microscopy of colloidal gold–labeled 
lipoproteins revealed that circulating VLDL rem-
nants are internalized by hepatocytes in the Arh–/– 
mice whereas LDL is not. The ability of hepatocytes 
to internalize β-VLDL but not LDL was recapitu-
lated in vitro in primary hepatocytes isolated from 
Arh–/– animals. These findings contrast with a prior 
report that Arh–/– hepatocytes grown ex vivo are 
competent to internalize LDL (30). It is possible that 
the difference in results in the 2 sets of experiments 
reflects differences in the time intervals between the 
procurement of the cells and the performance of 
the study. Our uptake studies were performed after 
the cells were maintained in culture for less than 18 
hours whereas the prior study used a longer interval 
(>48 hours). Alternatively, the differences may reflect 
differences in LDL preparation. In the present study, 
we removed all LDL aggregates prior to addition of 
LDL to the cultured cells.
The mechanistic basis for the differences in LDLR-
mediated uptake of LDL and β-VLDL in Arh–/– mice 
is not known. VLDL remnants contain multiple 
copies of apoE and bind with higher affinity to the 
LDLR than do LDLs, which bind the receptor via 
a single copy of apoB (23). Previously, Michaely et 
al. demonstrated that the LDLRs on the surface of 
Arh–/– lymphocytes have a reduced capacity to bind 
LDL relative to either VLDL or IgG-C7, suggesting 
that ARH may act as a competency factor for LDL 
binding (31). Arh–/–Ldlrh/h hepatocytes bound but 
did not internalize IgG-C7, suggesting that high-
affinity binding is not sufficient for internalization 
of ligand in Arh–/– cells. Thus, the differences in 
LDLR-mediated internalization of LDL and β-VLDL 
in Arh–/– cells appear not to be due to differences in 
affinity of the receptor for the ligand. An alternative possibility 
is that the multiple apoE peptides on each VLDL remnant may 
facilitate clustering of the LDLRs and bypass the requirement of 
ARH in internalization of the ligand-receptor complex. It is not 
known if clustering of LDLR is sufficient for internalization of 
the receptor, but clustering of APOER2 or VLDLR, 2 closely relat-
ed LDLR family members, has been shown to be sufficient for 
signaling through the PTB domain–containing adaptor protein 
Dab1 (32). To construct a surrogate multivalent ligand for VLDL 
remnant, we used protein A to assemble tetramers of the mono-
clonal anti-LDLR antibody IgG-C7. IgG-C7 tetramers bound effi-
ciently to the surfaces of Arh–/–Ldlrh/h hepatocytes, but the com-
plexes failed to be internalized at 37°C. Similarly, aggregation of 
LDL by vortexing did not result in uptake by ARH-deficient cells 
(data not shown). These findings do not support the notion that 
VLDL-mediated clustering of LDLRs obviates the need for ARH 
but also do not completely rule out this possibility. The multiple 
apoE moieties on VLDL remnants may adopt a conformation 
Figure 6
Internalization of IgG-C7 and IgG-C7:protein A complexes in primary hepatocytes. 
Primary hepatocytes were isolated from Arh+/+Ldlrh/h, Arh–/–Ldlrh/h, and Arh+/+Ldlr–/– 
mice and incubated for 1 hour at 4°C with either (A) IgG-C7 or (B) IgG-C7 complexed 
with protein A. Cells were then warmed to 37°C for 2 hours. IgG-C7 was detected by 
indirect immunofluorescence confocal microscopy. Original magnification, ×130.
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required for LDLR endocytosis that our antibody complexes or 
aggregated LDL did not replicate.
A third possibility is that VLDL remnants bind LDLRs that 
decorate the surface of Arh–/– hepatocytes but that internaliza-
tion is mediated by another cell surface component, such as 
LRP or heparan sulfate proteoglycans. Genetic deletion of LRP, 
which abolished the uptake of the α2-macroglobulin, did not 
reduce the uptake of β-VLDL by Arh–/– cells. Similarly, treatment 
of primary hepatocytes with heparinase did not affect β-VLDL 
uptake (Supplemental Figure 2). These data suggest that LRP 
and heparan sulfate proteoglycans are not required for LDLR-
dependent uptake of VLDL remnants in the absence of ARH. 
Nonetheless, we cannot exclude the possibility that another, as 
yet unidentified cell surface component, mediates ARH-inde-
pendent internalization of β-VLDL.
Prior studies also reported differences in the cellular uptake and 
metabolism of β-VLDL when compared with LDL (33, 34). Tabas 
et al. (33) reported that LDL and β-VLDL are delivered to different 
intracellular vesicles in mouse peritoneal macrophages; β-VLDL 
stimulated the activity of acyl-CoA/cholesterol acyltransferase 
activity whereas LDL did not. The difference in cellular traffick-
ing of the 2 lipoproteins was apparent early in their intracellular 
itinerary (33) and appeared to reflect differences in the endocytic 
mechanisms by which the lipoproteins were internalized (34). 
It is not known whether ARH contributes to differences in the 
uptake of LDL and β-VLDL in macrophages. Nonetheless, these 
studies raise the possibility that lipoproteins internalized by 
ARH-dependent and ARH-independent routes may have differ-
ent intracellular itineraries and metabolic effects.
Twisk et al. have shown that inactivation 
of the LDLR results in an increase in apoB 
secretion by cultured hepatocytes (35). We 
failed to find evidence for an increase in VLDL 
secretion rates in either the Arh–/– mice or the 
Ldlr–/– mice when we measured apoB secre-
tion in vivo. These results are consistent with 
other in vivo studies in mice that have failed 
to report an increase in apoB secretion in the 
absence of the LDLR (36, 37). Multiple factors 
may contribute to the differences in the results 
obtained when VLDL secretion is analyzed in 
cell culture and in vivo. Although we cannot 
rule out the possibility that subtle differences 
in VLDL synthesis among the Arh–/–, Ldlr–/–, 
and wild-type mice exist, they appear to play 
a more modest role than the differences in 
VLDL clearance in accounting for the lower 
plasma levels of cholesterol in the Arh–/– mice 
compared with the Ldlr–/– mice.
The results of this study provide insights 
into 2 paradoxical observations in ARH 
patients. LDL turnover studies have shown 
that the defect in clearance of circulating 
LDL in ARH patients is comparable to that 
of patients with homozygous FH, yet ARH 
patients have lower LDL-C levels and develop 
symptomatic coronary heart disease signifi-
cantly later in life. In FH, the rate of clearance 
of LDL precursor particles is decreased; there-
fore, the severe hypercholesterolemia associ-
ated with this condition results from an increase in LDL produc-
tion as well as a decrease in LDL clearance (1). If the clearance of 
VLDL remnants is preserved in ARH individuals as it is in Arh–/– 
mice, then LDL production rates would not be increased in these 
patients. Increasing LDLR expression should further enhance the 
removal of LDL precursors even in the absence of ARH, resulting 
in lower levels of LDL-C. The increased clearance of VLDL rem-
nants due to increased LDLR expression may explain the greater 
LDL-lowering effect of HMG-CoA reductase inhibitors in ARH 
compared with homozygous FH (1, 13–16, 18).
Methods
General methods. Cholesterol and triglyceride levels in the liver and plas-
ma were measured enzymatically as described previously (38). Plasma 
lipoprotein fractions were separated by fast-performance liquid chro-
matography (FPLC) using a Superose 6 column (Amersham Biosci-
ences), and the cholesterol content of the fractions was determined 
as described (29, 39). Protein concentrations were determined using 
the Lowry method (40). The anti-LDLR monoclonal antibody IgG-C7, 
which recognizes the second ligand-binding domain of the LDLR, was 
generated as described previously (24).
Lipoproteins.	 Human LDL (d = 1.019–1.063 g/ml) was prepared by 
sequential ultracentrifugation (41). β-VLDL (d < 1.006) was isolated from 
the plasma of cholesterol-fed rabbits as described (42). Mouse VLDL was 
prepared from the plasma of 30 Ldlr–/– mice fed a diet containing 1.25% 
cholesterol, 7.5% cocoa butter, 7.5% casein, and 0.5% cholic acid, and the 
mouse LDL was prepared from 80 Ldlr–/– mice fed a chow diet exactly as 
described (43). The LDL and β-VLDL were radiolabeled using the Bolton-
Hunter reagent (44), purchased from Amersham Biosciences. Fluorescent 
Figure 7
Deletion of LRP does not reduce β-VLDL clearance in Arh–/– mice. (A) Mice (n = 3 per 
group) were fasted for 4 hours, anesthetized with sodium pentobarbital, and injected with 
125I-labeled rabbit β-VLDL (15 μg) via the external jugular vein. Venous blood was collected 
from the retro-orbital plexus at the indicated times, and the plasma content of isopropanol-
precipitable 125I-radioactivity was measured. Radioactivity remaining in the plasma was 
plotted as a percentage of the activity present 2 minutes after injection of the labeled ligand. 
The experiment was repeated, and similar results were obtained. (B) Primary hepatocytes 
were isolated from Arh–/–Lrplox/loxCre– and Arh–/–Lrplox/loxCre+ mice and incubated overnight 
in DMEM containing 5% lipoprotein-deficient serum. The next morning, the cells were incu-
bated with 15 μg/ml DiI β-VLDL or 10 μg/ml methylamine-activated α2-macroglobulin (α2M) 
(51) for 30 minutes. The cells were washed, fixed, and mounted as described in Methods. 
Images were taken by deconvolution microscopy. Original magnification, ×84.
research article
172	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 117	 	 	 Number 1	 	 	 January 2007
LDL (PMCA-O LDL) was synthesized by reconstituting the lipid core of 
LDL with PMCA-O as described (45), with minor modifications. After 
reconstitution with PMCA-O, fluorescently labeled LDL monomers were 
separated from aggregated LDL via FPLC using a Superose 6 column. 
β-VLDL was fluorescently labeled with DiI as described (46). Colloidal gold–
labeled LDL and β-VLDL were produced as previously described (31, 47).
Mice and diets. All mice used in these studies were maintained on a hybrid 
genetic background of C57BL/6J and 129Sv strains. All protocols used in 
the studies described were approved by the Institutional Animal Care and 
Research Advisory Committee at the University of Texas Southwestern 
Medical Center. Comparisons were made among littermates. Mice with 
genetic disruption of Arh or Ldlr have been previously described (20, 48). 
Mice expressing the human LDLR at the endogenous mouse Ldlr locus 
(hLDLR knockin mice) (22) were crossed with the Arh–/– mice to develop 
mice expressing the human LDLR and no ARH (Ldlh/+Arh–/–). All mice 
were housed on a 12-hour dark/12-hour light cycle and maintained on 
standard chow containing 6% (w/w) animal fat and 0.02% (w/w) choles-
terol (Teklad 6% mouse/rat diet 7002; Harlan Teklad) as well as water 
ad libitum unless otherwise stated. The Western diet was synthesized by 
supplementing normal chow with 21% (w/w) anhydrous milk fat and 
0.2% cholesterol. The high-sucrose diet (no. 960237; MP Biomedicals) 
contained 60.2% sucrose, 20% casein, 15% cellulose, 0.3% dl-methionine, 
3.5% minerals and vitamins, and less than 0.2% fat.
Measurement of VLDL production. Mice were fasted for 6 hours at the 
beginning of the light cycle. The mice were anesthetized with sodium 
pentobarbital (80 mg/kg) and then injected in the external jugular vein 
with a bolus of 300 mg/kg Triton WR-1339 (Tyloxapol; Sigma-Aldrich) 
in 0.9% NaCl (15% Triton WR-1339; w/v). Blood samples were collected in 
EDTA-coated tubes (Microvette 500 KE; Sarstedt) from the retro-orbital 
plexus at the indicated time points. Aliquots of plasma from individual 
mice were measured for triglyceride content as described above. The 
remaining plasma was pooled, and VLDL was separated by ultracentri-
fugation over 0.9% NaCl at 436,000 g for 45 minutes. The VLDL frac-
tion was removed and precipitated with trichloroacetic acid. The pellet 
was washed in ice-cold acetone and resuspended in SDS sample buffer. 
Component apoproteins were then separated by 5% SDS PAGE. The gels 
were stained overnight in colloidal Coomassie blue (Invitrogen). Relative 
quantities of apo48 and apoB100 were determined by densitometry using 
ImageQuant 5.0 (Molecular Dynamics). Staining between gels was nor-
malized using a standard curve of human apoB100 included on each gel. 
The secretion rates of triglycerides were calculated by linear regression of 
plasma triglyceride concentrations against time.
Clearance of LDL and VLDL from plasma. Lipoproteins were radiolabeled 
with 125iodine, and clearance rates of LDL and VLDL were determined 
as previously described (48, 49). In brief, mice were anesthetized with 
sodium pentobarbital (80 mg/kg) and injected via the external jugular 
vein with a 0.2 ml bolus of either 125I-LDL (15 μg) or 125I-VLDL (15 μg) 
in 10 mM TrisCl, pH 7.4, 150 mM NaCl, and 0.2% (w/v) BSA. Venous 
blood was collected from the retro-orbital plexus in EDTA-coated tubes 
at the indicated times (Microvette 500 KE; Sarstedt). The plasma con-
tent of 125I-labeled apoB was measured by γ counting after isopropanol 
precipitation. The half-lives of VLDL and LDL were calculated from the 
decay curve of the lipoproteins. The amount of 125I-LDL or 125I-VLDL 
remaining in the plasma was expressed as a percentage of the initial con-
centration, measured as the amount of 125I-radioactivity in the plasma 
2 minutes after injection. The logarithm of the amount of lipoprotein 
remaining in the plasma was plotted against time, and the decay curve 
was fitted using a second-order polynomial equation.
In vivo uptake of colloidal gold–labeled LDL and VLDL. A total of approxi-
mately 50 μg of colloidal gold–labeled human LDL or rabbit β-VLDL was 
injected into the tail veins of male mice. The mice were sacrificed after 
2 hours and perfused via cardiac puncture with warm HBSS followed by 
4% paraformaldehyde (PFA) in PBS. The livers were removed, diced, and 
fixed with 2% glutaraldehyde and post-fixed in 1% (w/v) osmium tetrox-
ide. The specimens were rinsed in distilled water, dehydrated with grad-
ed ethanol, and then Epon-embedded according to the manufacture’s 
protocol (Electron Microscopy Sciences). Ultrathin sections (~80 nm) 
were cut with a diamond knife using a Leica ULTRACUT R ultramicro-
tome and placed on Formvar/carbon-coated nickel grids. Sections were 
stained with 3% aqueous uranyl acetate (15 minutes) and lead acetate 
(5 minutes). Electron micrographs were taken using a JEOL 1200 elec-
tron microscope operating at 80 kV.
Uptake of fluorescent lipoproteins by primary hepatocytes. Primary hepatocytes 
were isolated from mice of the indicated genotypes as described, with minor 
modifications (29). Mice were anesthetized and the livers perfused via the 
portal vein with 30 ml of prewarmed Liver Perfusion Media (17701-038; 
Invitrogen) followed by 30 ml prewarmed Liver Digest Media (17703-034; 
Invitrogen) at approximately 3 ml/min. The livers were removed from the 
animals, and the Glisson capsule was stripped. The dissociated cells were 
dispersed by shaking, followed by filtration through 100-μm nylon filter 
into an equal volume of cold buffer A (DMEM, 5% [v/v] fetal calf serum, 
100 μg/ml penicillin, 100 μg/ml streptomycin, 10 mM HEPES, pH 7.4). 
The cells were washed twice at 4°C with buffer A and counted with a hema-
cytometer, and 5 × 105 hepatocytes were plated onto collagen I–coated cov-
erslips (354089; BD Biosciences) in DMEM containing 5% (v/v) lipopro-
tein-deficient serum, 100 μg/ml penicillin, and 100 mg/ml streptomycin 
for 5 hours at 37°C. The cells were washed with PBS and incubated in 
DMEM containing 5% lipoprotein-deficient serum for 12 hours at 37°C 
in 5% CO2. A total of 25 μg/ml PMCA-O LDL or 25 μg/ml DiI VLDL was 
added to the medium. After the indicated time period, the hepatocytes 
were washed at 4°C twice for 10 minutes with buffer B (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 2 mg/ml BSA) and once briefly with buffer C 
(50 mM Tris-HCl, pH 7.4, 150 mM NaCl). Cells were then fixed with 4% 
PFA in buffer D (20 mM sodium phosphate, 150 mM NaCl, 2 mM MgCl2) 
at 25°C for 15 minutes. Cells were then briefly washed with 50 mM NH4Cl, 
then washed twice with buffer C and once with deionized H2O. Coverslips 
were mounted on slides with Shandon Immu-Mount (Thermo Electron 
Corp.). Images were acquired using a DeltaVision RT deconvolution micro-
scope running softWoRx Explorer Suite 1.1 (Applied Precision).
Internalization of monoclonal IgG and IgG:protein A complexes by primary 
hepatocytes. Primary hepatocytes were isolated as described (see above). 
Hepatocytes were washed with cold PBS and incubated at 4°C for 1 hour 
with 20 μg/ml IgG-C7 in medium A supplemented with 20 mM HEPES, 
pH 7.4. The cells were then warmed to 37°C for the times indicated, after 
which the coverslips were washed twice for 10 minutes with ice-cold buf-
fer B and once briefly with buffer C. The cells were fixed for 15 minutes at 
25°C with 4% PFA in buffer D, washed once in 50 mM NH4Cl and once 
in buffer D, and then permeabilized for 10 minutes at –10°C with 0.05% 
(v/v) Triton X-100 in buffer D. The cells were incubated for 1 hour at 
25°C in buffer D supplemented with 10% (v/v) goat serum and 20 mg/ml 
BSA and then for 2 hours in 20 μg/ml Alexa Fluor 534 goat anti-mouse 
antibody (Invitrogen) in the same buffer. The cells were washed 3 times 
with 1 mg/ml BSA in buffer D and once briefly in deionized water before 
mounting. Images were acquired using the Leica TCS SP laser scanning 
confocal microscope. IgG-C7 tetramers were formed by incubating IgG-C7 
and protein A at a 4:1 molar ratio in buffer D for 1 hour at room tempera-
ture. The IgG-C7:protein A complexes were diluted in medium A to a final 
concentration of 20 μg/ml of antibody and processed as described above. 
Formation of the complexes was confirmed by blue native polyacrylamide 
gel electrophoresis.
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Heparinase treatment of primary hepatocytes. Primary hepatocytes were 
isolated as described (see above). Hepatocytes were incubated at 37°C 
for 1 hour with fresh DMEM medium containing 5% lipoprotein-defi-
cient serum with or without 5 unit/ml heparinase (EC 4.2.2.7, Hepa-
rinase I; Sigma-Aldrich). DiI-labeled β-VLDL was added to the cells 
(10 μg/ml), and incubation at 37°C was continued for 2 hours. To test 
the activity of Heparinase I, Ldlrh/hArh+/+ hepatocytes were incubated with 
apoE-enriched β-VLDL. Before the addition to the cells, the β-VLDL 
and apoE were incubated together (5 and 7.5 μg of protein, respective-
ly, unless otherwise indicated) for 1 hour at 37°C. Human apoE3 was 
obtained as described (50). The cells were then washed with cold PBS, 
fixed with 4% PFA in buffer F (20 mM sodium phosphate, 150 mM NaCl, 
2 mM MgCl2) at 25°C for 5 minutes, and washed with PBS and water. 
Coverslips were mounted on slides and images were acquired using a 
DeltaVision RT deconvolution microscope running softWoRx Explorer 
Suite 1.1 (Applied Precision).
Statistics. The secretion rate of triglycerides and the half-lives of VLDL 
and LDL in Arh–/– and Ldlr–/– mice were compared with those of wild-type 
animals using 2-sample, 2-tailed Student’s t test.
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